Employees: 43
Size Heartseed (219A.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $392M, the 1191st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,733 on 18 Nov 2026.
Performance Over six months the shares gained 53.3%, against -18.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 196.9% over the last twelve months (peer median -13.1%); the operating margin is 9.0% (peer median -18.2%).
Valuation It trades at 21.9× enterprise value to sales against a peer median of 4.4× (6th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +73%, so the hurdle is -27 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 30.4 points above its cost of capital (6.1% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | ¥2.59B | ¥874M | ¥345M | ¥499M |
| Revenue growth | — | +197% | +153% | -31% | — |
| EBITDA | n/a | ¥279M | -¥997M | -¥1.45B | -¥1.46B |
| Net income | n/a | ¥163M | -¥813M | -¥1.47B | -¥1.41B |
| Free cash flow | n/a | ¥1.05B | -¥1.36B | -¥1.13B | -¥1.92B |
| Capital expenditure | n/a | ¥28.7M | ¥14.0M | ¥328M | ¥0 |
| Total debt | ¥500M | ¥252,000 | ¥5.39M | ¥11.6M | ¥31.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 219A.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.9% | -12.9% | 4th highest of 21 |
| 6-month return | +53.3% | -18.5% | 2nd highest of 20 |
| Distance from 52-week high | -14.9% | -47.4% | 2nd highest of 21 |
| Revenue growth (TTM) | +196.9% | -13.1% | 3rd highest of 19 |
| Operating margin | 9.0% | -18.2% | 4th highest of 19 |
| EV / Sales | 21.9× | 4.4× | 6th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 46.5% | 4.7% | most demanding of 7 |
| Growth delivered (Del g) | +73.2% | +11.7% | highest of 7 |
| Hurdle (Req g minus delivered) | -26.7 pp | -3.7 pp | least demanding of 7 |
| ROIC minus cost of capital | +30.4 pp | -3.6 pp | 2nd highest of 16 |
| Net debt / EBITDA | -20.6× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Heartseed 219A.T | Japan | $392M | +53% | +197% | 9% | 21.9× | 46.5% | +73.2% |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $388M | -17% | +9% | 19% | 2.2× | -5.5% | +12.2% |
| Avalo Therapeutics AVTX | United States | $387M | -59% | -69% | -161,961% | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | 71.6× | n/a | n/a |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | 32.0× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | 3.7× | 20.9% | +28.2% |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $398M | -13% | -3% | 2% | 3.4× | 14.9% | +13.7% |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | 6.2× | n/a | n/a |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $405M | -24% | +91% | -65% | 7.9× | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 2.9× | n/a | n/a |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $406M | -18% | -16% | 2% | 1.9× | 9.2% | +6.7% |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | 41.2× | n/a | n/a |
| Lumosa Therapeutics 6535.TWO | Taiwan | $406M | -37% | -25% | -803% | 399.1× | n/a | n/a |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $407M | -15% | -16% | 7% | 1.7× | -3.2% | +11.2% |
| CytomX Therapeutics CTMX | United States | $410M | -49% | -88% | -676% | 4.7× | n/a | n/a |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | 4.4× | n/a | n/a |
| Rezolute RZLT | United States | $411M | +32% | n/a | n/a | n/a | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $412M | +64% | +6,162% | -194% | 119.7× | n/a | n/a |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 1.2× | 0.1% | +0.3% |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | 2.9× | n/a | n/a |